Skip to main content
OpenTrials
Completed

NCT Number: NCT04857151

Stress, Inflammation and Immune Response Pilot Study- Aim 3

The overall goal of this study is to investigate the effects of stress and glucose intake at the molecular level including gene expression, protein and functional analysis of immune cells in real time.

Aim 1- Characterizing the immune response after acute stress and glucose consumption Aim 2- Temporal mapping of the modulation of immune cell function via meditation Aim 3-Influence of meditative practice on lupus patients Aim 4-Influence of meditative practice on healthy subjects

Current Clinicaltrials.gov record, will be focused on Aim-3 only. Aim-3 will test whether meditation alters neutrophil function and inflammation in patients with lupus. Study team will investigate whether patient neutrophils have altered NET formation, phagocytosis, ROS signaling and migration after ABMP. Innate immune function via analysis of monocytes by flow cytometry will also be analyzed. Other immune cell responses including CD8 T cells will also be investigated.

Completed

Looking for future studies?

Notify Me

Key information

Age range

21 year–65 year

Sex eligibility

Female

Study type

Interventional

Phase

Early Phase 1

Primary location

University of Wisconsin

Madison, Wisconsin, 53705, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Lupus diagnosis according to >4 ACR 1987 criteria or >4 SLICC 2012 criteria or a diagnosis confirmed by a board-certified rheumatologist
  • Capacity to provide informed consent and ability to speak and read English
  • BMI under 35
  • Must have access to an iOS or android smartphone to allow daily use of an app

Exclusion criteria

  • Currently participating in another clinical trial with intervention. Participation in observational clinical trials is not grounds for exclusion.
  • History of significant systemic disease (eg. cancer, infection, hematological, renal, hepatic, coronary artery disease or other cardiovascular disease, endocrinological (diabetes), neurologic, rheumatologic, or gastrointestinal disease)
  • Acute illness or evidence of clinically significant active infection
  • Pregnant, breast feeding or less than 6 months post-partum
  • Taking prescribed psychotropic or central nervous system altering medications
  • History of a diagnosed Bipolar Disorder, Schizophrenia, or Schizoaffective Disorder, epilepsy or seizures
  • Individuals who are currently undergoing a depressive episode. Can include those who are under treatment and not depressed currently.
  • Excluded based upon the screening visit
  • Use of nicotine
  • Significant previous training or significant current practice in meditation
  • Completed Mindfulness Based Stress Reduction (MBSR) in the past
  • Current meditation practice. Judgment: Participants will be included or excluded at the PIs discretion due to wide variation in responses (e.g. 2 people answer yes, one practices mindfulness 2x/week for 2 years (exclude), the other attends regular religious services (include))
  • Significant daily practice with other mind-body techniques
  • Daily Yoga or Tai Chi Practice - exclude
  • Other daily practice - judgment

Treatment and study plan

App based mindfulness program (ABMP)

Behavioral

App based mindfulness program (ABMP)

Primary outcomes

  1. Change in neutrophil function as assessed by Neutrophil extracellular trap(NET) formation

    Time frame: Baseline and 8 weeks

  2. Change in phagocytic index of neutrophils

    Time frame: Baseline and 8 weeks

    Neutrophil phagocytosis is measured by quantifying the ingestion of fluorescent zymosan or E.coli bioparticles using fluorescence microscopy. A phagocytic index is calculated to report the number of particles phagocytosed per cell.

  3. Change in neutrophil function as assessed by reactive oxygen species (ROS) production

    Time frame: Baseline and 8 weeks

  4. Change in neutrophils' migratory ability as assessed by change in neutrophils' velocity

    Time frame: Baseline and 8 weeks

    Neutrophil migration is assessed using time lapse microscopy. The migration patterns of individual neutrophils are measured using NIH Image J FIJI and velocity (μm/min) is measured.

  5. Change in neutrophils' migratory ability as assessed by change in "distance travelled" by neutrophils

    Time frame: Baseline and 8 weeks

    Neutrophil migration is assessed using time lapse microscopy. The migration patterns of individual neutrophils are measured using NIH Image J FIJI and distance (μm) is quantified.

  6. Change in the expression of stress-induced genes

    Time frame: Baseline and 8 weeks

Secondary outcomes

  1. Change in inflammatory cytokines level

    Time frame: Baseline and 8 weeks

    Peripheral blood mononuclear cells (PBMC) and sub-populations including CD8 T cells and NK cells will be isolated from blood to study inflammatory cytokines level.

  2. Change in expression of 'immune cells activation markers'

    Time frame: Baseline and 8 weeks

  3. Change in the monocyte activation level

    Time frame: Baseline and 8 weeks

    Monocytes will be analyzed by flow cytometry for activation markers and other markers of cell function.

  4. Change in the methylation pattern of stress-induced genes

    Time frame: Baseline and 8 weeks

  5. Change in the gene expression pattern of stress induced genes

    Time frame: Baseline and 8 weeks

  6. Change in the cytokine secretion level from immune cells

    Time frame: Baseline and 8 weeks

Other outcomes

  1. Change in PROMIS-GH (Patient-Reported Outcomes Measurement Information System Global Health) score

    Time frame: Baseline and 8 weeks

    PROMIS self-report measures are intended to be completed by the respondent without help from anyone else.

    The PROMIS GH is comprised of 10 global items. Each item represents a different domain of health. Mental health and physical health summary scores are computed and standardized to the general population. Both these component scores and individual global items can be used to assess patients' perceptions of their health.

    PROMIS global health can be converted to raw scores between 4-20 that can be converted to a t-score of 16.2-67.7. A higher score reflects better functioning.

  2. Change in State Trait Anxiety Inventory (STAI) Score

    Time frame: Baseline and 8 weeks

    The State Trail Anxiety Inventory is a 20 item questionnaire about how the participant is feeling. The total possible range of scores is 20-80 lower scores indicate less anxiety.

  3. Change in Five Facet Mindfulness Questionnaire (FFMQ)

    Time frame: Baseline and 8 weeks

    FFMQ is a 39-item questionnaire scored on a 5 pt likert scale for a total possible range of scores 39-195 where higher scores indicate increased mindfulness.

  4. Change in the Perceived Stress Scale

    Time frame: Baseline and 8 weeks

    The Perceived Stress Scale is a 10-item survey scored on a 5-pt likert scale for a total possible range of scores 0-40 where higher scores indicate increased perceived stress.

  5. Change in PROMIS-Positive Affect Score

    Time frame: Baseline and 8 weeks

    The PROMIS-Positive Affect Score is based on a 15-item survey, each item scored on a 5-pt likert scale for a total possible range of scores 15-75 where higher score indicated higher positivity.

  6. Change in PROMIS-Depression Score

    Time frame: Baseline and 8 weeks

    The PROMIS-Depression Score is based on a 6-item survey, each item scored on a 5-pt likert scale for a total possible range of scores 6-30 where higher score indicate increased depression.

Sponsors and collaborators

Lead sponsor

University of Wisconsin, Madison

Other

Registry information

Important dates

Study start
2022
Primary completion
2024
Study completion
2024
First posted
Apr 23, 2021
Registry last updated
May 16, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.